Other

Nipro Corporation

Mitsubishi Gas Chemical Company, Inc.

Kumamoto University

Dojindo Laboratories

Hiroshi Maeda

Nipro Corporaton

Takaaki Akaike

Masaki Otagiri

Teizi Urakami

Kazumi Sasamoto

Teruo Akuta

Tomohiro Sawa

Yu Ishima

Yoichi Miyamoto

Masaki Yoshida

Hideo Nishigoori

Chieko Yoshida

Ryusuke Tsunoda

Ken Okumura

Keizo Sato

Yoshiki Katayama

An object of the present invention is to provide a novel compound that is an agonist of guanosine-3',5&#x2032;-cyclic monophosphate and has an effect of activating protein kinase G. The present invention provides 8-guanosine-3&#x2032;,5&#x2032;-cyclic monophosphate compound which is represented by the following formula, and a pharmaceutical composition, especially a protein kinase G activating agent, which contains the 8-guanosine-3&#x2032;,5&#x2032;-cyclic monophosphate compound as an active ingredient. 

Nitroguanosine-3' 5&#x2032;-cyclic monophosphate compound and protein kinase G activating agent

A protein is efficiently nitrosylated with nitrogen monoxide by merely mixing S-nitrosoglutathione as a nitrogen monoxide donor with a protein solution containing a stabilizing agent comprising at least one compound or a combination of plural compounds selected from an N-acetylamino acid, a fatty acid, and a fatty acid salt. The method that enables efficient NO addition to a cysteine residue in un-nitrosylated protein without changing the structure of protein and hence provides NO to a living organism.

S-nitrosoprotein preparation and production method therefor

Method of producing S-nitrosoprotein preparation

An antitumor agent, which is a combination of an oxidoreductase, such as xanthine oxidase chemically conjugated to a polymer such as poly ethylene glycol, for initial administration and accumulation in the tumor tissue followed by administration and of a substrate for the oxidoreductase which releases reactive oxygen species. Improved tumor selective cytotoxic activity results.

Antitumor agents

The present invention provides a nitrosylated albumin variant wherein one or more amino acid residues of constituent amino acid sequences are substituted, or a different amino acid residue is inserted into a part of the constituent amino acid sequences. The albumin variant has sufficient antimicrobial property and permits application as various useful pharmaceutical compositions.

Albumin having enhanced antimicrobial activity

An antitumor agent, which is a combination of an oxidoreductase, such as xanthine oxidase chemically conjugated to a polymer such as poly ethylene glycol, for initial administration and accumulation in the tumor tissue followed by administration of a substrate for the oxidoreductase which releases reactive oxygen species. Improved tumor selective cytotoxic activity results.

A method for treatment of viral infections which comprises administering to the patients being suffering from said viral infections an effective amount of one or more substances selected from the group consisting of nitric oxide scavengers and nitric oxide synthase inhibitors. Said method for treatment of viral infections is useful in viral infections induced by influenza virus, herpes virus, hepatitis virus, cytomegalovirus, human immunodeficiency virus, etc.

Agent for treatment of viral infections

Antihypertensive agents containing as its active ingredient the 4-amino-6-hydroxypyrazolo �3,4-d!pyrimidine(AHPP) or its derivatives represented by the general formula (I) below. ##STR1## where R is hydrogen atom, alkyl group or aryl group.

Method for treating hypertension using pyrazolopyrimidine derivatives

This invention offers the compounds which exhibit a coronary blood vessel dilating action which is long-acting. (Constitution) Novel imidazolinoxyl derivatives represented by a general formula (1). A compound A in which R is COOH is given in an example. ##STR1## (Merit) The compounds of the present invention can be directly administered, after diluting to a suitable concentration with a phosphate buffer or the like, to blood vessel which is required to be relaxed and dilated whereby a significant and long-acting relaxing action is resulted though, in a blood flow, they are quickly inactivated and excreted and no side effect is noted.

Imidazolinoxyl derivatives

2-phenyl-4,4,5,5-tetramethylimidazoline-1-oxyl-3-oxide derivatives and

Pyrrolo quinoline esters, oxazopyrrolo quinolines and esters of oxazopyrrolo quinolines are effective at treating cataracts through their active oxygen scavenging activity.

Growing community of inventors

Kumamoto, Japan

Takaaki Akaike